No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
ALLO Allogene Therapeutics
- 1.870
- +0.030+1.63%
Close Dec 20 16:00 ET
- 1.900
- +0.030+1.60%
Post 17:42 ET
392.09MMarket Cap-1.21P/E (TTM)
1.930High1.780Low4.99MVolume1.790Open1.840Pre Close9.34MTurnover3.29%Turnover RatioLossP/E (Static)209.67MShares5.77552wk High0.85P/B284.03MFloat Cap1.78052wk Low--Dividend TTM151.89MShs Float55.000Historical High--Div YieldTTM8.15%Amplitude1.780Historical Low1.870Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $9
CAR T-cell Therapy Strategic Business Research Report 2024-2030: Allogeneic `Off-the-Shelf` CAR T-Cell Therapies Generate New Opportunities in Manufacturing - ResearchAndMarkets.com
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why
Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?
Heat List
US
Overall
Symbol
Price
% Chg
No Data